.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Chinese Patent Office
Baxter
Boehringer Ingelheim
Dow
QuintilesIMS
Covington
Daiichi Sankyo
Chubb
Colorcon

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 091544

« Back to Dashboard

NDA 091544 describes LITHIUM CARBONATE, which is a drug marketed by Able, Alembic Ltd, Apotex Inc, Glenmark Generics, Hetero Labs Ltd Iii, Mylan Pharms Inc, Usl Pharma, Watson Labs, West-ward Pharms Int, Alembic Pharms Ltd, Barr, Glenmark Pharms Inc, Heritage Pharma, Hikma Intl Pharms, Unique Pharm Labs, Pfizer, and Sun Pharm Inds Inc, and is included in twenty-nine NDAs. It is available from thirty-three suppliers. Additional details are available on the LITHIUM CARBONATE profile page.

The generic ingredient in LITHIUM CARBONATE is lithium carbonate. There are fifteen drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the lithium carbonate profile page.

Summary for 091544

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Bipolar Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 091544

Medical Subject Heading (MeSH) Categories for 091544

Suppliers and Packaging for NDA: 091544

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LITHIUM CARBONATE lithium carbonate TABLET, EXTENDED RELEASE;ORAL 091544 ANDA Glenmark Pharmaceuticals Inc., USA 68462-223 68462-223-01 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (68462-223-01)
LITHIUM CARBONATE lithium carbonate TABLET, EXTENDED RELEASE;ORAL 091544 ANDA Avera McKennan Hospital 69189-0526 69189-0526-1 1 TABLET, FILM COATED, EXTENDED RELEASE in 1 DOSE PACK (69189-0526-1)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength300MG
Approval Date:Dec 27, 2010TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Farmers Insurance
Fish and Richardson
Moodys
Fuji
Boehringer Ingelheim
Chubb
Argus Health
Federal Trade Commission
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot